Metagenics – CandiBactin – BR 90 tabs

Metagenics - CandiBactin - BR 90 tabs

Herbal Supplement Concentrated Berberine Formula for Intestinal Support Supplement Facts Serving Size: 2 Tablets Servings per Container: 45 Amount per Serving Coptis (Coptis chinensis) Root & Rhizome 12:1 30 mg Extract (containing berberine) Oregon Grape (Berberis aquifolium) Root 4:1 Extract 70 mg Berberine HCIÊ 400 mg A 4:1ÊÊ proprietary extract of: 300 mg Coptis (Coptis chinensis) Root & Rhizome, Chinese Skullcap (Scutellaria baicalensis) Root, Phellodendron (Phellodendron chinense) Bark, Ginger (Zingiber officinale) Rhizome, Chinese Licorice (Glycyrrhiza uralensis) Root, Chinese Rhubarb (Rheum officinale) Root & Rhizome* Other Ingredients: Microcrystalline cellulose, croscarmellose sodium, silica, stearic acid (vegetable), magnesium stearate (vegetable), and coating (water, hypromellose, medium chain triglycerides, and hydroxypropylcellulose). ÊBerberine from Phellodendron amurense bark extract. ÊÊEquivalent to 1200 mg raw, dried, unprocessed herbs. DIRECTIONS: Take two tablets two to three times daily or as directed by your healthcare practitioner. WARNING: Do not use if pregnant or nursing. CAUTION: If taking medication including cyclosporine, consult your healthcare practitioner before use. Keep out of the reach of children. *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Here are all the ingredients in this product. Not what you are looking for? Click here. Click on any ingredient below to get a complete selection of all products containing that ingredient.Active Ingredients:Baikal Skullcap (Scutellaria baicalensis or Chinese skullcap) Berberine Chinese Rhubarb Rhizome Coptis (Coptis chinensis) Ginger (Zingiber officinale) Licorice (Glycyrrhiza glabra) Oregon Grape Root Phellodendron Rhubarb Inactive Ingredients:Cellulose, Croscarmellose, Hypromellose, Magnesium stearate, Mediu

Discount Price: £29.99
Buy from Amazon




Comments are closed.